Merck & Company, Inc. (MRK), headquartered in Rahway, New Jersey, provides a range of drugs and vaccines globally. With a market cap of $322.1 billion, its flagship drug, Keytruda, has been pivotal in oncology, alongside vaccines like Gardasil. This breadth sustains Merck's robust revenue growth and leadership in healthcare innovation.
The mega-cap stock has underperformed the broader market over the past 52 weeks. MRK has gained 14.5% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 26.6%. However, in 2024, shares of the drug maker are up 20.3%, outpacing SPX's 11.3% gains on a YTD basis.
